Autoimmune encephalitis in children

Journal of Child Neurology

Volumn 27, Issue 11, 2012, Pages 1460-1469

  Armangue, Thaís ^a   Petit Pedrol, Mar ^a   Dalmau, Josep ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anti NMDA receptor; autoimmune; encephalitis; limbic; NMDA

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RITUXIMAB;

ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE ENCEPHALITIS; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG MEGADOSE; ELECTROENCEPHALOGRAPHY; ENCEPHALITIS; EPILEPSY; EPILEPTIC STATE; HASHIMOTO ENCEPHALOPATHY; HUMAN; HYPOTHALAMUS FUNCTION DISORDER; HYPOVENTILATION; IMMUNOTHERAPY; INFERTILITY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; RASMUSSEN SYNDROME; REVIEW;

BRAIN DISEASES; CHILD; HASHIMOTO DISEASE; HUMANS; IMMUNOTHERAPY; PEDIATRICS;

EID: 84867725071     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073812448838     Document Type: Review

References (95)

1. Gable MS, Gavali S, Radner A, et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis. 2009 ; 28: 1421-1429
2. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011 ; 77: 179-189
3. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008 ; 7: 1091-1098
4. Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010 ; 10: 835-844
5. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012 ; 54: 899-904
6. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011 ; 10: 63-74
7. Irani SR, Bera K, Waters P, et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010 ; 133 (pt 6). 1655-1667
8. Titulaer MJ, McCracken L, Gabilondo I. Clinical Features, Treatment and outcome of 500 patients with anti-NMDA receptor encephalitis [abstract].. 2012 ; 78 ( meeting abstracts 1 ):
9. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009 ; 66: 11-18
10. Luca N, Daengsuwan T, Dalmau J, et al. Anti-N-methyl-d-aspartate receptor encephalitis: a newly recognized inflammatory brain disease in children. Arthritis Rheum. 2011 ; 63: 2516-2522
11. Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. "Extreme delta brush": a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. In press ;:
12. Bayreuther C, Bourg V, Dellamonica J, Borg M, Bernardin G, Thomas P. Complex partial status epilepticus revealing anti-NMDA receptor encephalitis. Epileptic Disord. 2009 ; 11: 261-265
13. Pruss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology. 2010 ; 75: 1735-1739
14. Frechette ES, Zhou L, Galetta SL, Chen L, Dalmau J. Prolonged follow-up and CSF antibody titers in a patient with anti-NMDA receptor encephalitis. Neurology. 2011 ; 76 (7 suppl 2). S64 - S66
15. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010 ; 30: 5866-5875
16. Iizuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology. 2008 ; 70: 504-511
17. Ishiura H, Matsuda S, Higashihara M, et al. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology. 2008 ; 71: 1921-1923
18. Wong-Kisiel LC, Ji T, Renaud DL, et al. Response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis. Neurology. 2010 ; 74: 1550-1551
19. Kashyape P, Taylor E, Ng J, Krishnakumar D, Kirkham F, Whitney A. Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with cyclophosphamide: the need for early aggressive immunotherapy in tumour negative paediatric patients. Eur J Paediatr Neurol. 2012 ; 16: 74-78
20. Kayser MS, Kohler CG, Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry. 2010 ; 167: 1039-1050
21. Tham SL, Kong KH. A case of anti-NMDAR (N-methyl-D-aspartate receptor) encephalitis: A rehabilitation perspective. NeuroRehabilitation. 2012 ; 30: 109-112
22. Houtrow AJ, Bhandal M, Pratini NR, Davidson L, Neufeld JA. The rehabilitation of children with anti-N-methyl-d-aspartate-receptor encephalitis: a case series. Am J Phys Med Rehabil. 2012 ; 91: 435-441
23. Alexopoulos H, Kosmidis ML, Dalmau J, Dalakas MC. Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. J Neurol. 2011 ; 258: 1568-1570
24. Sansing LH, Tuzun E, Ko MW, Baccon J, Lynch DR, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol. 2007 ; 3: 291-296
25. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 ; 123 (pt 7). 1481-1494
26. Howard RS, Lees AJ. Encephalitis lethargica. A report of four recent cases. Brain. 1987 ; 110 (pt 1). 19-33
27. Dale RC, Irani SR, Brilot F, et al. N-methyl-d-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol. 2009 ; 66: 704-709
28. Creten C, van der Zwaan S, Blankespoor RJ, et al. Late onset autism and anti-NMDA-receptor encephalitis. Lancet. 2011 ; 378: 98
29. Dhossche DM, Wachtel LE. Catatonia is hidden in plain sight among different pediatric disorders: a review article. Pediatr Neurol. 2010 ; 43: 307-315
30. Kolker S, Christensen E, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I-revised recommendations. J Inherit Metab Dis. 2011 ; 34: 677-694
31. Kurian MA, Gissen P, Smith M, Heales S, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011 ; 10: 721-733
32. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 ; 75: 1135-1140
33. Graus F, Saiz A. Limbic encephalitis: a probably under-recognized syndrome [in Spansh]. Neurologia. 2005 ; 20: 24-30
34. Dalmau J. Recognizing paraneoplastic limbic encephalitis. J Clin Oncol. 2009 ; 27: e230 - e231
35. Corsellis JA, Goldberg GJ. Norton AR. "Limbic encephalitis" and its association with carcinoma. Brain. 1968 ; 91: 481-496
36. Tuzun E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist. 2007 ; 13: 261-271
37. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010 ; 9: 776-785
38. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010 ; 133: 2734-2748
39. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004 ; 127 (pt 3). 701-712
40. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011 ; 69: 892-900
41. Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?. Neurology. 2011 ; 76: 1355-1357
42. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009 ; 65: 424-434
43. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010 ; 9: 67-76
44. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011 ; 77: 1698-1701
45. Haberlandt E, Bast T, Ebner A, et al. Limbic encephalitis in children and adolescents. Arch Dis Child. 2011 ; 96: 186-191
46. Akman CI, Patterson MC, Rubinstein A, Herzog R. Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency. Dev Med Child Neurol. 2009 ; 51: 563-567
47. Carr I. The Ophelia syndrome: memory loss in Hodgkin's disease. Lancet. 1982 ; 1: 844-845
48. Gregorios JB, Roldan E, Davis J, Curless R. Encephalomyelitis associated with leukemia in a child. J Child Neurol. 1987 ; 2: 293-297
49. Meyer JJ, Bulteau C, Adamsbaum C, Kalifa G. Paraneoplastic encephalomyelitis in a child with neuroblastoma. Pediatr Radiol. 1995 ; 25 (suppl 1). S99 - S101
50. Rosenbaum T, Gartner J, Korholz D, et al. Paraneoplastic limbic encephalitis in two teenage girls. Neuropediatrics. 1998 ; 29: 159-162
51. Alink J, de Vries TW. Unexplained seizures, confusion or hallucinations: think Hashimoto encephalopathy. Acta Paediatr. 2008 ; 97: 451-453
52. Berger I, Castiel Y, Dor T. Paediatric Hashimoto encephalopathy, refractory epilepsy and immunoglobulin treatment-unusual case report and review of the literature. Acta Paediatr. 2010 ; 99: 1903-1905
53. Bektas O, Yilmaz A, Kendirli T, Siklar Z, Deda G. Hashimoto encephalopathy causing drug-resistant status epilepticus treated with plasmapheresis. Pediatr Neurol. 2012 ; 46: 132-135
54. Castro-Gago M, Gomez-Lado C, Maneiro-Freire M, Eiris-Punal J, Bravo-Mata M. Hashimoto encephalopathy in a preschool girl. Pediatr Neurol. 2010 ; 42: 143-146
55. Hoffmann F, Reiter K, Kluger G, et al. Seizures, psychosis and coma: severe course of hashimoto encephalopathy in a six-year-old girl. Neuropediatrics. 2007 ; 38: 197-199
56. Tamagno G, Celik Y, Simo R, et al. Encephalopathy associated with autoimmune thyroid disease in patients with Graves' disease: clinical manifestations, follow-up, and outcomes. BMC Neurol. 2010 ; 10: 27
57. Tamagno G. How should we denominate the encephalopathy occurring in patients with an autoimmune thyroid disease?. Acta Paediatr. 2011 ; 100: 5-6
58. Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006 ; 63: 197-202
59. Bohnen NI, Parnell KJ, Harper CM. Reversible MRI findings in a patient with Hashimoto's encephalopathy. Neurology. 1997 ; 49: 246-247
60. Dogan M, Acikgoz E, Acikgoz M, Cesur Y, Ariyuca S, Bektas MS. The frequency of Hashimoto thyroiditis in children and the relationship between urinary iodine level and Hashimoto thyroiditis. J Pediatr Endocrinol Metab. 2011 ; 24: 75-80
61. Zois C, Stavrou I, Kalogera C, et al. High prevalence of autoimmune thyroiditis in schoolchildren after elimination of iodine deficiency in northwestern Greece. Thyroid. 2003 ; 13: 485-489
62. Tuzun E, Erdag E, Durmus H, et al. Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis. Neurol India. 2011 ; 59: 47-50
63. Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005 ; 128 (pt 3). 454-471
64. Hart YM, Andermann F, Fish DR, et al. Chronic encephalitis and epilepsy in adults and adolescents: a variant of Rasmussen's syndrome?. Neurology. 1997 ; 48: 418-424
65. Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science. 1994 ; 265: 648-651
66. Degenhardt A, Duvoisin RM, Frennier J, et al. Absence of antibodies to non-NMDA glutamate-receptor subunits in paraneoplastic cerebellar degeneration. Neurology. 1998 ; 50: 1392-1397
67. Alvarez-Baron E, Bien CG, Schramm J, Elger CE, Becker AJ, Schoch S. Autoantibodies to Munc18, cerebral plasma cells and B-lymphocytes in Rasmussen encephalitis. Epilepsy Res. 2008 ; 80: 93-97
68. Bien CG, Bauer J, Deckwerth TL, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol. 2002 ; 51: 311-318
69. Gahring L, Carlson NG, Meyer EL, Rogers SW. Granzyme B proteolysis of a neuronal glutamate receptor generates an autoantigen and is modulated by glycosylation. J Immunol. 2001 ; 166: 1433-1438
70. Bauer J, Elger CE, Hans VH, et al. Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann Neurol. 2007 ; 62: 67-80
71. Thilo B, Stingele R, Knudsen K, et al. A case of Rasmussen encephalitis treated with rituximab. Nat Rev Neurol. 2009 ; 5: 458-462
72. Dabbagh O, Gascon G, Crowell J, Bamoggadam F. Intraventricular interferon-alpha stops seizures in Rasmussen's encephalitis: a case report. Epilepsia. 1997 ; 38: 1045-1049
73. Maria BL, Ringdahl DM, Mickle JP, et al. Intraventricular alpha interferon therapy for Rasmussen's syndrome. Can J Neurol Sci. 1993 ; 20: 333-336
74. Bien CG, Gleissner U, Sassen R, Widman G, Urbach H, Elger CE. An open study of tacrolimus therapy in Rasmussen encephalitis. Neurology. 2004 ; 62: 2106-2109
75. Bien CG, Schramm J. Treatment of Rasmussen encephalitis half a century after its initial description: promising prospects and a dilemma. Epilepsy Res. 2009 ; 86: 101-112
76. Sakuma H, Awaya Y, Shiomi M, et al. Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis. Acta Neurol Scand. 2010 ; 121: 251-256
77. van BA, Stephani U, Kluger G, Hausler M, Dulac O. FIRES: febrile infection responsive epileptic (FIRE) encephalopathies of school age. Brain Dev. 2009 ; 31: 91-93
78. Mikaeloff Y, Jambaque I, Hertz-Pannier L, et al. Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis. Epilepsy Res. 2006 ; 69: 67-79
79. Specchio N, Fusco L, Claps D, Vigevano F. Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis. Brain Dev. 2010 ; 32: 51-56
80. Carranza RD, Simon HA, Iona X, et al. Febrile infection-related epilepsy syndrome is not caused by SCN1A mutations. Epilepsy Res. 2012 ; 100: 194-198
81. Suleiman J, Brenner T, Gill D, et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology. 2011 ; 76: 1252-1255
82. Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs. 2005 ; 22: 8-19
83. Pranzatelli MR, Tate ED, Verhulst SJ, et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol. 2010 ; 32: e167 - e172
84. Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord. 2004 ; 19: 770-777
85. Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol. 2000 ; 22: 315-320
86. Blaes F, Fuhlhuber V, Korfei M, et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol. 2005 ; 58: 313-317
87. Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr. 2007 ; 166: 359-363
88. Pohl KR, Pritchard J, Wilson J. Neurological sequelae of the dancing eye syndrome. Eur J Pediatr. 1996 ; 155: 237-244
89. Ize-Ludlow D, Gray JA, Sperling MA, et al. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. Pediatrics. 2007 ; 120: e179 - e188
90. Bougneres P, Pantalone L, Linglart A, Rothenbuhler A, Le SC. Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood. J Clin Endocrinol Metab. 2008 ; 93: 3971-3980
91. De PL, Trochet D, Caillat-Zucman S, et al. Delineation of late onset hypoventilation associated with hypothalamic dysfunction syndrome. Pediatr Res. 2008 ; 64: 689-694
92. Nunn K, Ouvrier R, Sprague T, Arbuckle S, Docker M. Idiopathic hypothalamic dysfunction: a paraneoplastic syndrome?. J Child Neurol. 1997 ; 12: 276-281
93. Ouvrier R, Nunn K, Sprague T, et al. Idiopathic hypothalamic dysfunction: a paraneoplastic syndrome?. Lancet. 1995 ; 346: 1298
94. Huppke P, Heise A, Rostasy K, Huppke B, Gartner J. Immunoglobulin therapy in idiopathic hypothalamic dysfunction. Pediatr Neurol. 2009 ; 41: 232-234
95. Paz-Priel I, Cooke DW, Chen AR. Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome. J Pediatr. 2011 ; 158: 337-339